DiaSorin S.p.A. (OTCMKTS:DSRLF) Given Average Rating of “Reduce” by Analysts

DiaSorin S.p.A. (OTCMKTS:DSRLF) has received a consensus recommendation of “Reduce” from the six research firms that are currently covering the stock, Marketbeat Ratings reports. Four research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and one has issued a buy recommendation on the company.

Several analysts recently commented on DSRLF shares. Piper Sandler began coverage on shares of DiaSorin in a research note on Thursday, June 11th. They issued a “neutral” rating for the company. UBS Group downgraded shares of DiaSorin from a “hold” rating to a “sell” rating in a research report on Wednesday, August 12th. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of DiaSorin in a research note on Tuesday, August 4th. Zacks Research downgraded DiaSorin from a “hold” rating to a “strong sell” rating in a research note on Thursday, August 6th. Finally, BNP Paribas Exane cut DiaSorin from a “neutral” rating to an “underperform” rating in a report on Tuesday, July 7th.

DiaSorin Stock Performance

OTCMKTS DSRLF opened at $86.00 on Friday. The business’s 50 day moving average is $80.42 and its two-hundred day moving average is $76.72. DiaSorin has a 12-month low of $66.50 and a 12-month high of $100.00.

DiaSorin Company Profile

DiaSorin S.p.A. is an Italy?based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over?the?counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.